A research contact and engagement platform for investigators interested in using mitoquinol in clinical or preclinical research. MCRP provides a direct pathway for academic and clinical researchers to connect with the MitoQ scientific team to discuss the research use of mitoquinol within ethically approved and scientifically rigorous study designs.
A pilot clinical trial examining whether Mitoquinol initiated within 72 hours of high‑risk SARS‑CoV‑2 exposure reduces infection rates and symptom duration, including in unvaccinated and immunocompromised individuals.
A double‑blind crossover trial examining whether 4 weeks of Mitoquinol supplementation restores immune cell bioenergetics in patients with heart failure with preserved ejection fraction (HFpEF).
A randomised crossover trial assessing whether acute supratherapeutic doses of Mitoquinol produce any evidence of kidney injury in healthy adults, using sensitive renal biomarkers.
A 21‑day supplementation trial examining whether Mitoquinol reduces exercise‑induced nuclear and mitochondrial DNA damage without impairing adaptive training signals.
